Brief reportsAnalysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion☆
References (12)
- et al.
Effect of pravastatin on plasma markers of inflammation and peripheral endothelial function in male heart transplant recipients
Am J Cardiol
(2001) - et al.
Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial
J Am Coll Cardiol
(2003) Lipid-lowering therapy for prevention of ventricular tachyarrhythmias
J Am Coll Cardiol
(2003)- et al.
Atrial fibrillation impairs endothelial function of forearm vessels in humans
J Card Fail
(2001) - et al.
Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription
Circulation
(2000) Statins as potent antiinflammatory drugs
Circulation
(2002)
Cited by (125)
Bioconversion of mevastatin to pravastatin by various microorganisms and its applications – A review
2018, Biocatalysis and Agricultural BiotechnologyA new score for detection of early cardioversion using intravenous amiodarone in recent onset atrial fibrillation
2016, Egyptian Heart JournalCitation Excerpt :Our analysis did not confirm a correlation between the time of amiodarone cardioversion and dyslipidemia, and the intake of statins had no statistically significant difference in the time of cardioversion. Despite the results of Tveit et al.17 suggest that lipid-lowering drug use is associated with a significant reduction in AF risk, the role of lipid-lowering drugs in the treatment of preexisting AF is not elucidated by this study and remains controversial. In this study we found that smoking has no significant effect on time of amiodarone cardioversion.
Statin therapy lowers the risk of new-onset atrial fibrillation in patients with end-stage renal disease
2015, International Journal of CardiologyAtrial Fibrillation Coincides with the Advanced Glycation End Product N<sup>ε</sup>-(Carboxymethyl)Lysine in the Atrium
2015, American Journal of PathologyThe preventive effect of statin therapy on new-onset and recurrent atrial fibrillation in patients not undergoing invasive cardiac interventions: A systematic review and meta-analysis
2013, International Journal of CardiologyCitation Excerpt :The studies were homogeneous (I2 = 31% and p = 0.14 for heterogeneity). Among the RCTs four out of eleven trials were categorized as having high potential risk of bias [17,30,31,38]. Assessing exclusively the 16 observational studies, statin treatment showed a significant risk reduction (RR: 0.813 [95%CI: 0.79–0.83], p < 0.001).
- ☆
This study was supported by Bristol-Myers Squibb Norway Ltd., Oslo, Norway, whose support covered all costs of the study medication.